Bionic 3D spheroids biosensor chips for high-throughput and dynamic drug screening
To perform the drug screening, planar cultured cell models are commonly applied to test efficacy and toxicity of drugs. However, planar cultured cells are different from the human 3D organs or tissues in vivo. To simulate the human 3D organs or tissues, 3D spheroids are developed by culturing a small aggregate of cells which reside around the extracellular matrix and interact with other cells in liquid media. Here we apply lung carcinoma cell lines to engineer the 3D lung cancer spheroid-based biosensor using the interdigitated electrodes for drug efficacy evaluation. The results show 3D spheroid had higher drug resistance than the planar cell model. The anticarcinogen inhibition on different 3D lung cancer spheroid models (A549, H1299, H460) can be quantitatively evaluated by electric impedance sensing. Besides, we delivered combination of anticarcinogens treatments to A549 spheroids which is commonly used in clinic treatment, and found the synergistic effect of cisplatin plus etoposide had higher drug response. To simultaneously test the drug efficacy and side effects on multi-organ model with circulatory system, a connected multiwell interdigitated electrode arraywas applied to culture different organoid spheroids. Overall, the organization of 3D cancer spheroids-based biosensor, which has higher predictive value for drug discovery and personalized medicine screening, is expected to be well applied in the area of pharmacy and clinical medicine.
KeywordsBionic 3D spheroid chips 3D cancer spheroid Cancer model Drug screening Personalized medicine
This work was supported by National Natural Science Fund of China (No. 61320106002, 31627801, 31661143030) and National 973 project (No. 2015CB352101).
- I. Giaever, C.R. Keese, Use of electric fields to monitor the dynamical aspect of cell behavior in tissue culture. IEEE Trans. Biomed. Eng. (2), 242–247 (1986)Google Scholar
- G. Huang, J. Pan, Z. Ye, B. Fang, W. Cheng, Z. Cao, Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget 8(61), 104206 (2017)Google Scholar
- Y. Li, T. Zhou, C. Ma, W. Song, J. Zhang, Z. Yu, Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells. J. Thorac. Dis. 7(3), 400 (2015)Google Scholar
- F. Salimi, K.A. Dilmaghani, E. Alizadeh, A. Akbarzadeh and S. Davaran, Enhancing cisplatin delivery to hepatocellular carcinoma HepG2 cells using dual sensitive smart nanocomposite. Artificial cells, nanomedicine, and biotechnology:, 1–10 (2017)Google Scholar
- S. Surget, M.P. Khoury, J.C. Bourdon, Uncovering the role of p53 splice variants in human malignancy: A clinical perspective. Onco Targets Ther 7, 57 (2014)Google Scholar